Kairos Pharma Earnings Call Transcripts
Fiscal Year 2025
-
Interim phase II data for ENV105 plus apalutamide in mCRPC show a median PFS of 13.7 months and a favorable safety profile, with manageable side effects and no unexpected toxicities. Experts view the early efficacy and resensitization to hormone therapy as promising for this patient population.
-
Kairos Pharma presented advances in reversing cancer drug resistance with ENV105, showing strong safety and efficacy in prostate and lung cancer trials. Key data readouts are expected in September 2024, with a focus on large market opportunities and strategic pharma partnerships.
-
The company is advancing a pipeline targeting cancer drug resistance and immune suppression, with lead programs in prostate and lung cancer and a strong focus on biomarker-driven trials. Near-term milestones include key safety and efficacy readouts and major conference presentations in early 2025.
Fiscal Year 2024
-
Multiple clinical trials are underway targeting drug resistance in cancer, supported by strong NIH funding and a recent IPO. A novel antibody approach restores drug sensitivity across several cancer types, with interim efficacy data expected in early 2025. The company targets large oncology markets and leverages strategic partnerships for cost-effective trials.
-
Kairos Pharma is advancing CD105-targeted therapies to reverse cancer drug resistance, with phase 2 and phase 1 trials in prostate and lung cancer, respectively. Biomarker-driven strategies and a novel immunotherapy pipeline support a robust clinical outlook, with key safety and efficacy readouts expected in the coming year.